secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001104659-25-029370
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement
------------------------------------------------------------------------------

- Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.
- Company has 45 days (until May 9, 2025) to submit a Compliance Plan to Nasdaq.
- If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
- If plan rejected, common stock subject to delisting; company can appeal to Hearing Panel.
- Company cautions no assurance that plan will be accepted or compliance regained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925029370/0001104659-25-029370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925029370/tm2510590d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer